More on NVS
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $161.01 |
|
|||
| Open | $156.71 | ||||
| 52 Wk High | $89.15 | ||||
| 52 Wk Low | $69.84 | ||||
| Day High | $160.54 | ||||
| Day Low | $156.18 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 3,765,305 | ||||
- Novartis shareholders approve 5.7% dividend increase at annual meeting
- Novartis (NOVN:SW) (NVS) PT Lowered to CHF92 at Berenberg
- Novartis completes $12 billion Avidity Biosciences acquisition
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- Novartis receives positive European opinion for CSU treatment remibrutinib
- Novartis to build radioligand therapy site in Texas to expand US manufacturing
- Unnatural Products, Novartis sign licensing agreement for cardiovascular program
- Novartis reports positive results for remibrutinib in chronic urticaria
- Novartis (NVS) PT Raised to $180 at TD Cowen
- Form 144 NOVARTIS AG Filed by: Marshall Fiona
Entities mentioned with NVS
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
